ClinicalTrials.gg
Not yet recruitingNCT07493122Updated Mar 25, 2026

Study of IMC-S118AI in Type 1 Diabetes

A Phase 1 interventional study of IMC-S118AI in Type 1 Diabetes, Type 1 Diabetes (T1D) and Diabetes Type 1, sponsored by Immunocore Ltd. Not yet recruiting. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Immunocore Ltd · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.

02

Conditions studied

  • Type 1 Diabetes
  • Type 1 Diabetes (T1D)
  • Diabetes Type 1

Keywords

  • diabetes
  • type 1
03

In context

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's planned enrollment of 154 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Immunocore Ltd is the lead sponsor of 15 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI): 18 to 25 kg/m2
  • History of a diagnosis of T1D
  • HLA type: HLA-A*02:01
  • Shows signs of remaining beta-cell function

Exclusion criteria

Exclusion Criteria:

  • Non-T1D (type 2 diabetes, monogenic diabetes, and secondary diabetes)
  • History of recurrent hypoglycaemia due to non-compliance with insulin regimens
  • Prior treatment with immunomodulating therapy for T1D
  • Have a history of cardiovascular disease or impaired cardiac function
  • Current diagnosis of a or any history of malignancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Single Ascending Dose

    Participants receive single ascending doses of IMC-S118AI.

    Biological: IMC-S118AI

  • Experimental
    Multiple Ascending Dose

    Participants receive multiple ascending doses of IMC-S118AI.

    Biological: IMC-S118AI

Interventions

  • BiologicalIMC-S118AI

    IMC-S118AI solution for infusion/injection

06

What researchers measure

Primary outcomes

  1. Number of participants with ≥1 treatment-emergent serious adverse event (SAE)

    Time frame: Up to 60 weeks

  2. Number of participants with ≥1 treatment-emergent adverse event (AE)

    Time frame: Up to 45 weeks

  3. Number of participants with clinically significant changes in safety laboratory parameters

    Time frame: Up to 45 weeks

  4. Number of participants with clinically significant changes in vital signs

    Time frame: Up to 45 weeks

  5. Number of participants with clinically significant changes in electrocardiogram (ECG)

    Time frame: Up to 45 weeks

  6. Number of participants with dose interruptions, reductions, or discontinuations

    Time frame: Up to 21 weeks

Secondary outcomes

  1. Plasma concentration of IMC-S118AI

    Time frame: Up to 21 weeks

  2. Number of participants with anti-IMC-S118AI antibody formation

    Time frame: Up to 31 weeks

  3. AUC of serum C-peptide after a 2 h MMTT at Week 25

    Time frame: Week 25

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Nov 2030, 55 months later.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 55 months is above that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 25, 2026
StartEst.
Apr 2026
Primary completionEst.
Nov 2030
CompletionEst.
Nov 2030
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07493122
Lead sponsor
Immunocore Ltd
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Apr 2026 (estimated)
Primary completion
Nov 2030 (estimated)
Completion
Nov 2030 (estimated)
Last update
Mar 25, 2026

Study contacts

Immunocore Medical Information
Contact
medical.information@immunocore.com
844-466-8661
Immunocore Medical Information EU
Contact
medinfo.eu@immunocore.com
+00 800-744-51111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion